Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexFemale
Age18+
SponsorRutgers, The State University of New Jersey
About this trial
This study proposes that the addition of statins reduces the treatment delays or early discontinuations secondary to cardiotoxicity in patients with Stage I-III HER2 positive breast being treated with anti-HER2 therapy.
Eligibility criteria
Qualifiers
Histologically and/or cytologically confirmed diagnosis of Stage I-III female breast cancer (including inflammatory breast cancer)
Scheduled to receive neoadjuvant/adjuvant HER2 targeted therapy
Between ≥18 years of age
Female patients of childbearing potential must have a negative pregnancy test (serum or urine) prior to enrollment. Female patients must agree to use effective barrier contraception during the period of therapy
Disqualifiers
Participants with stage IV breast cancer
Participants currently taking statins
Uncontrolled hypertension (systolic blood pressure >190 mm Hg or diastolic blood pressure >100 mm Hg)
No active liver disease
Trial design
Treatments tested in this trial
- Lipitor 40mg Tablet
Treatment groups
60 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov